NCT01355718View on ClinicalTrials.gov

Observational, Safety Study of NovoNorm® (Repaglinide) and Insulin Analogue Combination Therapy in Type 2 Diabetes in Korea

CompletedOBSERVATIONAL

Enrollment

120

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

DiabetesDiabetes Mellitus, Type 2

Interventions

DRUG

repaglinide

The dosage and frequency, as well as later changes to either dose, frequency or add-on medication (if applicable), will be determined by the physician, according to the patient's requirements.

Trial Locations (1)

137-920

Seoul